Overweight And Obesity clinical trials

Explore recruiting overweight and obesity clinical trials.

Recruiting overweight and obesity studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Overweight And Obesity trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The effects of tirzepatIDE on coronAry pLaque lipid content and myocardial microvascular function in people with overweight or obesity and CORonary disease

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity and type 2 diabetes

Czechia, Romania, Croatia, Slovakia, Hungary

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of cagrilintide for weight management in participants with overweight or obesity

Norway, France, Italy, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of cagrilintide s.c. in combination with semaglutide s.c. (CagriSema s.c.) once-weekly in participants with overweight or obesity

Spain, Finland, Belgium, Germany, Italy, France +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effect of an adjunctive intervention on the tolerability of semaglutide in overweight adults without diabetes: a prospective, randomised, double-blind, single-centre, placebo-controlled clinical trial (SEMTOL)

Estonia

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus.

Germany, Spain, Czechia, Poland, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

Overweight And Obesity trials by city

Overweight And Obesity in Toronto Overweight And Obesity in Vancouver Overweight And Obesity in Montreal Overweight And Obesity in Calgary Overweight And Obesity in Edmonton Overweight And Obesity in Ottawa Overweight And Obesity in Winnipeg Overweight And Obesity in Quebec City Overweight And Obesity in Hamilton Overweight And Obesity in Kitchener Overweight And Obesity in London Overweight And Obesity in Halifax Overweight And Obesity in New York Overweight And Obesity in Los Angeles Overweight And Obesity in Chicago Overweight And Obesity in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease